Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.

[1]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[2]  E. Vicaut,et al.  Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.

[3]  R. Ferrari,et al.  Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). , 2014, Journal of the American College of Cardiology.

[4]  M. Jeong,et al.  Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.

[5]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[6]  Chao-Yung Wang,et al.  Lesion Length Impacts Long Term Outcomes of Drug-Eluting Stents and Bare Metal Stents Differently , 2013, PloS one.

[7]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[8]  J. Marchesini,et al.  Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.

[9]  M. Jeong,et al.  Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.

[10]  I. Seong,et al.  Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. , 2011, JACC. Cardiovascular interventions.

[11]  G. Lemesle,et al.  Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation: A Review of the Current Guidelines and Literature , 2011, Hospital practice.

[12]  R. Califf,et al.  2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[13]  E. Antman,et al.  2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[14]  G. Lemesle,et al.  Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  I. Seong,et al.  A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces , 2011, Journal of the American College of Cardiology.

[16]  M. Jeong,et al.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.

[17]  G. Lemesle,et al.  Drug-eluting stents: issues of late stent thrombosis. , 2010, Cardiology clinics.

[18]  A. Kastrati,et al.  Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. , 2009, European heart journal.

[19]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[20]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[21]  F. Verheugt,et al.  Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.

[22]  G. Lemesle,et al.  Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. , 2009, American heart journal.

[23]  Seung‐Jung Park,et al.  Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. , 2008, JACC. Cardiovascular interventions.

[24]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[25]  E. Camenzind,et al.  Response to Letter Regarding Article, “Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern” , 2007 .

[26]  William Wijns,et al.  A Cause for Concern , 2007 .

[27]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[28]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[29]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[30]  I. Seong,et al.  Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease , 2006, Circulation.

[31]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[32]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[33]  C. Di Mario,et al.  Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.

[34]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[35]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .